The BPaL TB regimen patent India ruling turns on a scientific question as much as a legal one: does combining three known antibacterial medicines into a short regimen create something new and inventive? According to press reports, the Indian Patent Office answered no in an order dated 27 October 2026, rejecting TB Alliance’s application on grounds including lack of novelty, no inventive step, non-patentability and insufficient disclosure. This article looks at the clinical evidence context for the regimen, how earlier publications figure in the dispute, and what the ruling does and does not tell us about patient access.
BPaL TB regimen patent India: evidence in brief
- BPaL combines bedaquiline, pretomanid and linezolid; BPaLM adds moxifloxacin.
- Opponents reportedly argued that studies published in 2015 already disclosed the combination and its shorter-regimen use.
- The Patent Office reportedly found lack of novelty and inventive step, among other grounds.
- The ruling does not change the clinical evidence for the regimen.
- TB Alliance had not commented, so its scientific arguments in the proceedings are not public in the sources.
The components behind the BPaL TB regimen patent India dispute
Bedaquiline is a diarylquinoline antibacterial used in drug-resistant TB. Pretomanid is a nitroimidazole. Linezolid is an oxazolidinone antibiotic widely used for resistant infections. Moxifloxacin, added in BPaLM, is a fluoroquinolone. Each component has its own development history and regulatory status, which is why questions of novelty arise when they are combined. The World Health Organization maintains background and guidance on TB treatment.
What the clinical record says in the BPaL TB regimen patent India context
Published studies, including the Nix-TB trial, have reported high rates of favourable outcomes with the BPaL combination in people with highly drug-resistant TB, and the WHO has recommended BPaLM as a shorter all-oral option in its drug-resistant TB guidance. We have not re-verified trial figures for this article, so readers should consult the publications and WHO guidance directly. The patent ruling does not question whether the regimen works; it concerns whether the application met the legal tests for a patent in India.
Why prior publications matter in the BPaL TB regimen patent India case
Patent novelty depends on what was already public. Press reports say the oppositions argued that the combination and its use in a shorter regimen were disclosed in studies published in 2015. If an earlier publication discloses the same combination for the same use, a later claim to it may fail for lack of novelty. Inventive step asks a related question: would the combination have been obvious to a skilled person given the earlier work? The reports describe the order as finding both lacking, though we have not seen the order.
Legal tests in the BPaL TB regimen patent India ruling
Reports say the order invoked provisions of the Patents Act including Sections 3(d), 3(e) and 3(i). In general terms, Section 3(d) limits patents on new forms of known substances unless efficacy is significantly improved, Section 3(e) concerns mere admixtures, and Section 3(i) concerns methods of treatment. The reports do not name the controller and we cannot confirm how each section was applied. Patent filings in India are administered by the Indian Patent Office.
Who raised the BPaL TB regimen patent India oppositions
According to press reports, pre-grant oppositions were filed in July 2020 by groups including the Delhi Network of Positive People, Sankalp Rehabilitation Trust, Third World Network, Lawyers Collective and the MSF Access Campaign. TB Alliance, a non-profit that develops TB medicines and describes its work on its website, reportedly did not attend the final hearings and had not responded to requests for comment.
Burden of disease behind the BPaL TB regimen patent India debate
Press reports cite about 2.71 million TB cases in India in 2024, around a quarter of the global total, or 187 per 100,000 people, as a WHO estimate, and say more than 15,000 patients in the national programme have started BPaLM. Drug-resistant TB is a smaller subset of this burden, and the sources do not give its size. See our Pharmaceutical coverage.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Infectious Disease Market report values the global market at USD 26.4 billion in 2022 and projects more than USD 50.7 billion by 2032, a CAGR of 6.9% for 2023 to 2032, with North America at 40% and Asia Pacific growing around 8% a year. TB appears only in passing and the growth figures do not fully reconcile, so these are broad context and not a TB forecast.
Timeline of the BPaL TB regimen patent India dispute
- 2015: studies cited by opponents are published.
- July 2020: pre-grant oppositions filed.
- 27 October 2026: order rejecting the application, as reported.
- 29 October 2026: press coverage.
General background: patents on combinations
Combination regimens raise special patent questions because each active ingredient may already be known. Offices examine whether the combination produces a new technical effect and whether the claimed use was already described. Outcomes differ between jurisdictions, as reports of patents granted in 11 countries and a rejection in India illustrate.
Our analysis of the BPaL TB regimen patent India ruling
In our assessment, the BPaL TB regimen patent India ruling shows how published trial literature can later serve as prior art against a regimen built from the same data. For researchers, the practical lesson is that publication timing and claim drafting interact with patent strategy. The decision says nothing about clinical efficacy.
What is not disclosed about the BPaL TB regimen patent India ruling
- The full order and the name of the controller.
- Whether TB Alliance will appeal.
- How each statutory ground was applied.
Risks and caveats
This article relies on press reports and general knowledge, and we have not seen the order. It is news reporting and not medical or legal advice.
What to watch next
- Appeal filings.
- Release of the order.
- Guidance updates on drug-resistant TB regimens.
FAQ
Does the ruling affect how well BPaL works?
No. It concerns patentability, not clinical efficacy.
What are the grounds?
Reportedly lack of novelty, no inventive step, non-patentability and insufficient disclosure.
Can it be appealed?
Usually yes, but no appeal has been reported.
How we reported this: we relied on press reports of the decision, public pages from the WHO, TB Alliance and the Indian Patent Office, and the Acumen Research and Consulting report cited above. We have not seen the order. Last updated 30 October 2026. This is news reporting and not advice.
